MedTrace Logo

Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery

NCT06500143 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2026-01-16

No results posted yet for this study

Summary

Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying. The goal of this study is to evaluate the effect of GLP-1RA on the effectiveness of fasting before a scheduled surgery.

The question it aims to answer is: does this kind of medication increase the risk of having food or too much liquid in the stomach before a scheduled surgery, even if the minimum 6 hour fast is done?

For this project, researchers will use gastric ultrasound to compare participants already taking one of these medications as part of their home treatment to participants who are not taking them. Gastric ultrasound is a simple bedside exam using an echography machine that takes less than 5 minutes to do.

Participants will:

-Have a gastric ultrasound performed on them before their surgery

Conditions

  • Gastric Retention

Interventions

DIAGNOSTIC_TEST

Gastric ultrasound

Using a curved array low-frequency abdominal probe (2-5 MHz) with abdominal presets and with the patient in right lateral decubitus position, the gastric antrum will be identified in a standardized plane at the level of the aorta. The stomach will be considered empty if the antrum appears flat or round with anterior and posterior walls collapsed. Normal gastric secretions and clear fluids have an anechoic or hypoechoic aspect on ultrasonography. Solid or thick fluids have a hyperechoic aspect and can create "ring-down" artifacts blurring gastric content, its posterior wall, the pancreas and the aorta. Following qualitative examination, quantitative assessment will be performed if there is presence of clear fluids. The cross-sectional area (CSA) of the antrum will be measured with three measurements to calculate a mean value.

Sponsors & Collaborators

  • Institut de Cardiologie de Montréal

    collaborator UNKNOWN

  • Ciusss de L'Est de l'Île de Montréal

    lead OTHER

Principal Investigators

  • Louis Morisson, MD, MSc · CIUSS de l'Est de l'Île de Montréal

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-09
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06500143 on ClinicalTrials.gov